My Best Weight

Call Directions Website Contact the business

My Best Weight A NEW approach to managing weight - Our clinic provides evidence based medical management for those

21/10/2026

DR PLEASE 2/8 — R = Regular Eating

We’re trying to regulate appetite, not eliminate it.

Obesity is a chronic neuroendocrine disease involving dysregulation of appetite, satiety and food reward pathways in the brain. Much of this happens subconsciously — it’s not simply a matter of willpower.

GLP-1-based medications can help quiet these powerful biological signals.

But there’s an important distinction between reducing the pathological drivers of obesity and suppressing normal physiological hunger and appetite.

Appetite has a purpose. It helps drive adequate nutrition, enjoyment of food and quality of life.

Profound appetite suppression or aversion to food isn’t the goal of treatment. It can be an unwanted effect that needs attention.

When appetite becomes extremely reduced, people may find themselves skipping meals and relying on small amounts of convenient foods throughout the day — sometimes replacing balanced, nutritious meals they previously enjoyed.

Eating less doesn’t necessarily mean eating well. The quality and adequacy of nutrition can suffer, even when someone feels they’re responding well to medication.

Long gaps without eating can also make it harder to meet nutritional needs, while larger meals later may contribute to nausea, bloating or uncomfortable fullness.

That’s why R = Regular Eating is part of DR PLEASE — helping people maintain adequate nutrition and improve tolerability, particularly when starting treatment or increasing their dose.

The goal is better appetite regulation, not maximum appetite suppression.

A quieter appetite should improve your relationship with food and your quality of life — not compromise your nutrition.

💡 DR PLEASE is my 8-part framework of practical advice to help people get the most from obesity medications while improving tolerability, nutrition and long-term treatment sustainability.

The full guide is available free on the My Best Weight website — link in bio.

www.mybestweight.ie

If you’re regularly struggling to eat or drink enough, or experiencing persistent side effects, discuss this with your prescribing healthcare professional.

19/10/2026

Blood pressure medication isn’t cheating. Insulin isn’t cheating. So why are GLP-1s for obesity? 🙃

Obesity isn’t a test of willpower, and treatment isn’t a morality contest.

There are no bonus points for struggling without effective treatment.

Using evidence-based medication to manage a chronic disease isn’t cheating.

Healthcare isn’t cheating. The stigma is the problem.

17/10/2026

D is for Dose — DR PLEASE 1/8

Obesity medications should be prescribed for the person, not for the timetable.

The right dose is not automatically the next dose — or the highest dose. It is the dose that gives meaningful benefit while remaining tolerable, affordable and sustainable.

That balance will differ from person to person, and it can change over time. Good prescribing means reviewing response, side effects, cost and what is realistic for long-term treatment — not simply escalating because another four weeks have passed.

This is the first of 8 practical DR PLEASE reels on making obesity medication treatment safer, more tolerable and more sustainable.

The full DR PLEASE guide is free on the My Best Weight website — link in bio.

www.mybestweight.ie

Dose changes should be discussed with your prescribing healthcare professional.

04/10/2026

Calling something a “peptide” tells you about its structure - not its evidence. It does not mean proven, safe or suitable for use as medicine.

When considering any of these products, there are two separate questions:

1️⃣ What do we know about the molecule?

Has it demonstrated benefits in good-quality human trials? Do we understand its side effects, interactions and longer-term risks?

For products such as BPC-157 and TB-500, there is little or no good-quality human evidence supporting many of the benefits being promoted.

Retatrutide is different. It is a genuine investigational medicine with phase 3 human evidence—but it has not yet been authorised by any medicines regulator, and its benefits and risks are still being evaluated.

2️⃣ What do we know about the product?

Does the vial contain the correct substance and amount? How was it manufactured and formulated? Was sterile production maintained? Is it consistent between batches? Has it remained stable during transport and storage?

A product sold directly to consumers as “Reta” is not the same thing as authorised retatrutide.

Independent testing can provide information about the particular sample and the specific things tested. But it cannot recreate regulated manufacturing or guarantee every vial, every batch, sterile production, appropriate storage or clinical safety.

Individual experiences can be genuine and important—but they cannot answer either of these questions reliably or establish effectiveness, uncommon harms or long-term safety.

Cost, access and fear of losing previous health gains are real concerns. We should acknowledge why people may turn to unregulated products without offering false reassurance about the risks.

Being evidence-based is not being anti-innovation. It is how promising science becomes safe, effective medicine.

Demonstrated benefit.
Evaluated risk.
Regulated manufacture.

That’s medicine… not biohacking.

19/09/2026

Too early for women. Too late for men.

That is, of course, a simplification — but it reflects a pattern I see repeatedly in obesity care.

Too many women have spent years, sometimes decades, being taught that their body size is something to monitor, control or fix. Diet culture brings women into conversations about weight long before anyone asks what it means for their health.

Men often have a different experience. A larger body can be more socially acceptable, particularly when associated with strength, sport or masculinity. In clinic, I frequently meet men later — after a new diagnosis, a health scare, a referral from another specialist, or sometimes after seeing a partner benefit from obesity treatment.

Neither experience is ideal.

Women do not need more pressure to become smaller. They need healthcare that asks about health, function, complications and individual need — and offers evidence-based obesity care when appropriate.

Men should not have to wait until sleep apnoea, high blood pressure, diabetes or another complication makes obesity feel like a legitimate health issue.

These differences are not simply about who “cares more” about their health. They reflect decades of different expectations about weight, bodies, masculinity, femininity and who is supposed to take responsibility for health.

Obesity care should not begin with shame, body-size scrutiny or a health scare.

The conversation should start with health.

08/09/2026

Stable does not mean ineffective.

A plateau can feel unsettling—especially when appetite or food noise becomes more noticeable than during the response phase, although usually remaining better regulated than before treatment. This does not necessarily mean that treatment has stopped working. Maintenance is still active treatment.

What does the evidence show?

• In STEP 5, the average response to semaglutide 2.4 mg plateaued around week 60 and was maintained to week 104 with continued treatment.

• In SURMOUNT-MAINTAIN, participants were approximately 22% below baseline after 60 weeks on tirzepatide 10 or 15 mg. At week 112, those continuing that dose remained 21.9% below baseline, compared with 16.6% after reducing to 5 mg and 9.9% after switching to placebo. Because placebo was followed for only 52 weeks, 9.9% may not have been the final position.

• An Oxford-led BMJ review of 37 studies estimated regain after stopping at 0.4 kg per month and return to baseline at 1.7 years; for semaglutide and tirzepatide, the estimates were 0.8 kg per month and 1.5 years. These are modelled averages, not individual predictions.

• ATTAIN-MAINTAIN examined continued treatment by switching to once-daily oral orforglipron. After 72 weeks on tirzepatide, participants were 21.5% below baseline and remained 16.8% below baseline after 52 weeks on orforglipron. After 72 weeks on semaglutide, the corresponding figures were 16.5% and 15.1%.

Maintenance does not automatically mean a lower dose, and reducing, changing or stopping treatment may mean preserving less of the response.

Response moves towards the level supported by the particular medication and dose taken long term—not necessarily the level reached during the initial response phase on a different treatment.

Treatment should be individualised around health, response, side effects, affordability and sustainability.

References:
- Garvey WT et al. STEP 5. Nature Medicine, 2022.
- Horn DB et al. SURMOUNT-MAINTAIN. The Lancet, 2026.
- Aronne LJ et al. ATTAIN-MAINTAIN. Nature Medicine, 2026.
- West S et al. BMJ, 2026;392:e085304.

04/09/2026

A glimpse into some of today’s clinic conversations.

Obesity is a fascinating area of medicine and an incredibly rewarding one in which to work. It’s a real privilege to support people in improving their health and managing obesity.

If any of these topics interest you, drop a comment below and I can explore them in more detail in future Reels.

01/09/2026

When a healthcare provider uses a patient’s body to promote treatment, one person’s experience becomes a marketing claim.

A carefully selected result is anecdote - not evidence. It cannot show the typical response, variation between people, adverse effects or whether any change was sustained. Lighting, posture, clothing, filters, Photoshop and AI can make the comparison even less reliable.

And it is only a snapshot.

We do not know what happened between the photographs, what the experience cost physically or psychologically - or what happened five years later.

We would not advertise treatment for diabetes or high blood pressure using photographs of patients’ bodies. Why should obesity care be different?

These images act as social triggers: the “before” is presented as the state to escape and the “after” as the state to pursue. That can reinforce unrealistic expectations, weight stigma, body dissatisfaction and disordered eating. It is familiar diet-culture marketing, now wrapped around biological treatments.

The fictional dolls in this Reel intentionally mirror that visual convention to critique it - not to suggest that one body is healthier, happier or more desirable than another.

Consent also changes over time. Someone may agree to share an image today and later withdraw that consent. The original can be deleted, but screenshots, reproductions and altered or stolen copies may remain online indefinitely.

People should be free to tell their own stories. Healthcare providers should not turn those stories - or their bodies - into advertisements.

Good obesity care should be evidence-based, individualised and judged by medical and metabolic health, mobility, psychosocial health, long-term health and quality of life.

You are not a “before.”
You are not an “after.”

The problem isn’t the medication. It’s when marketing replaces medicine.This fictional graphic is deliberately ridiculou...
26/08/2026

The problem isn’t the medication. It’s when marketing replaces medicine.

This fictional graphic is deliberately ridiculous. The questions behind it are not.

Obesity medications can be valuable, evidence-based treatments. Online care can also be excellent. This post critiques the models of care used by some providers—not people seeking treatment. The concern is when convenient access to a product is presented as comprehensive clinical care.

Red flags may include aggressive marketing, a focus on speed or guaranteed results, pressure to start immediately, referral codes or paid testimonials, vague information about risks and adverse effects, and no clear explanation of alternatives. Other concerns include no direct clinical conversation, limited access to an identifiable and appropriately qualified prescriber, and little or no follow-up after a prescription is issued.

A prescription should sit within an individualised treatment plan: comprehensive assessment, shared decision-making, clear guidance about options, dosing and adverse effects, a plan for what to do if concerns arise, and ongoing review.

Patients should understand why treatment is considered appropriate, how to use it safely, what to expect at different stages, which symptoms should prompt medical advice, how adverse effects will be managed, when treatment will be reviewed and who to contact if problems arise. A prescription without clear information, continuity or follow-up is not the same as comprehensive care.

Response should be considered in terms of health, function, quality of life and the person’s experience—not the scale alone.

Customer-service teams and automated systems may support care, but they cannot carry clinical responsibility.

Decisions requiring informed consent and clinical judgement should be guided by evidence, individual circumstances and patient preferences—not commercial pressure.

Obesity is a complex chronic disease. Access to medication matters. What surrounds the prescription matters too.

20/08/2026

Obesity treatment should not make food joyless - enjoying food and improving your health are not opposing goals.

When people feel they need to pause obesity medication to “enjoy eating”, it raises a bigger question: have we allowed the same old diet-culture cycle of restriction and permission to shape how we think about treatment?

Complete appetite suppression is not the goal. Neither is eating as little as possible or losing all enjoyment in food.

But they are two sides of the same diet-culture mindset: restriction in everyday life, permission on special occasions, then back to restriction again.

Complete appetite suppression is not the aim of treatment. Neither is losing all pleasure in food.

Good treatment should offer another path: helping to regulate appetite and reduce food preoccupation while supporting adequate nutrition, enjoyable meals, better health and a better quality of life.

Obesity care has to work in real life—not only at home, but in restaurants, at celebrations and on holiday.

If medication is making food unpleasant, causing troublesome side effects or affecting your quality of life, that is not something you should simply have to endure. Speak to your prescriber; the dose or treatment plan may need to be reviewed.

Good treatment should help people live more freely, it should fit into our lives and make that life better - not create another set of rules you need a holiday from.

Address

Unit 1, The Courtyard, 19 Castle Street
Dalkey
A96A8F8

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+35312546930

Website

Alerts

Be the first to know and let us send you an email when My Best Weight posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to My Best Weight:

Shortcuts

Share

Category